Transposon Receives Investment from the Alzheimers Drug Discovery Foundation to Support Advancement of TPN-101 for the Treatment of Alzheimers Disease
Summary
Transposon Therapeutics received an investment from the Alzheimer's Drug Discovery Foundation to advance TPN-101 for Alzheimer's disease. The company plans to start a Phase 2 clinical trial in the fourth quarter of 2025. Transposon is also continuing development of TPN-101 in the Phase 2/3 HEALEY ALS Platform trial. The release highlights prior Phase 2 results in PSP and ALS and positions TPN-101 as a potential treatment across multiple neurodegenerative diseases.
Funding
Amount
$5.0M
Total raised
Date
July 9, 2025
Announcement date
Investors
Alzheimer's Drug Discovery Foundation Diagnostics Accelerator
Lead investors
Company
https://transposonrx.com/
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected